Type of Document Dissertation Author Wang, Jie URN etd-12042010-030217 Title MYC and PIM1 synergism in prostate cancer Degree PhD Department Cancer Biology Advisory Committee
Advisor Name Title Vito Quaranta Committee Chair Fritz Parl Committee Member Robert Matusik Committee Member Sarki Abdulkadir Committee Member Simon Hayward Committee Member Keywords
- Neuroendocrine cancer
- Prostate cancer
Date of Defense 2010-11-22 Availability unrestricted AbstractThe oncogenic PIM1 kinase has been implicated as a cofactor for the oncogene c-MYC in prostate carcinogenesis. In this study, we show that co-expression of c-MYC and PIM1 is associated with high Gleason grade in prostate cancer. Using a tissue recombination model coupled with lentiviral-mediated gene transfer we show that Pim1 is weakly oncogenic in naive adult mouse prostatic epithelium. However, it cooperates dramatically with c-MYC to induce prostate cancer within 6 weeks. Importantly, c-MYC and Pim1 synergy is critically dependent on Pim1 kinase activity. c-MYC/Pim1 expressing tumors showed increased phosphorylation of MYC on serine 62. Expression of a phosphomimetic c-MYC S62D mutant resulted in higher rates of proliferation compared to that of wild type c-MYC. However, c-MYC S62D did not result in tumors like c-MYC/Pim1 grafts, indicating that Pim1 cooperativity with c-MYC involves additional mechanisms other than enhancement of c-MYC activity by S62 phosphorylation. In addition, c-MYC/Pim1-induced prostate carcinomas demonstrate evidence of neuroendocrine (NE) differentiation. Additional studies, including the identification of tumor cells co-expressing androgen receptor and NE cell markers synaptophysin and Ascl1 suggest that NE tumors arise from adenocarcinoma cells through transdifferentiation. These results directly demonstrate functional cooperation between c-MYC and Pim1 in prostate tumorigenesis in vivo and support therapeutic strategies for targeting PIM1 in prostate cancer.
Since Pim1 deficiency is well tolerated in vivo, it has been proposed that Pim1 inhibition may offer an attractive option to impede prostate cancer progression. In the current study, we used small hairpin interfering RNA (shRNA) directed against Pim1 to determine the anti-tumor effects in prostate cancer cell lines. In mouse c-MYC/Pim1 prostate tumor-derived cells and human prostate cancer cells, Pim1 knockdown markedly decreased cellular proliferation, survival, and tumorigenicity. Further studies indicate that in prostate cancer cells, Pim1 is required to maintain ERK/MAPK signaling pathway activation. Thus, Pim1 is necessary to maintain tumorigenicity, and may represent an efficient target for prostate cancer therapy.
(Note: Human MYC and mouse Pim1 are cloned in lentiviral constructs and used for this study)
Filename Size Approximate Download Time (Hours:Minutes:Seconds)
28.8 Modem 56K Modem ISDN (64 Kb) ISDN (128 Kb) Higher-speed Access Jie.pdf 5.10 Mb 00:23:35 00:12:08 00:10:37 00:05:18 00:00:27